Abstract |
In this study, the carbamate structure of pseudo-irreversible butyrylcholinesterase (BChE) inhibitors was optimized with regard to a longer binding to the enzyme. A set of compounds bearing different heterocycles (e.g., morpholine, tetrahydroisoquinoline, benzimidazole, piperidine) and alkylene spacers (2 to 10 methylene groups between carbamate and heterocycle) in the carbamate residue was synthesized and characterized in vitro for their binding affinity, binding kinetics, and carbamate hydrolysis. These novel BChE inhibitors are highly selective for hBChE over human acetycholinesterase (hAChE), yielding short-, medium-, and long-acting nanomolar hBChE inhibitors (with a half-life of the carbamoylated enzyme ranging from 1 to 28 h). The inhibitors show neuroprotective properties in a murine hippocampal cell line and a pharmacological mouse model of Alzheimer's disease (AD), suggesting a significant benefit of BChE inhibition for a disease-modifying treatment of AD.
|
Authors | Matthias Hoffmann, Carina Stiller, Erik Endres, Matthias Scheiner, Sandra Gunesch, Christoph Sotriffer, Tangui Maurice, Michael Decker |
Journal | Journal of medicinal chemistry
(J Med Chem)
Vol. 62
Issue 20
Pg. 9116-9140
(10 24 2019)
ISSN: 1520-4804 [Electronic] United States |
PMID | 31609115
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carbamates
- Cholinesterase Inhibitors
- Neuroprotective Agents
- Butyrylcholinesterase
|
Topics |
- Alzheimer Disease
(prevention & control)
- Animals
- Butyrylcholinesterase
(adverse effects)
- Carbamates
(chemistry)
- Cholinesterase Inhibitors
(chemistry, pharmacology)
- Disease Models, Animal
- Mice
- Neuroprotective Agents
(chemistry, pharmacology)
|